Jill Wechsler, Pharm Exec’s Washington Correspondent
Articles
Congress Slated to Reauthorize User Fees, Without FDA ‘Improvements’
Seek pared-down measure in funding bill to avert shutdown.
Clinical Trial Modernization Raises FDA Compliance Issues
Agency officials express associated concerns around clinical trial data reliability and quality.
Advanced Biopharma Manufacturing Key to White House Cancer Moonshot
Administration launches national manufacturing initiative, with aim to reduce US reliance on biomedicine from China and other regions.
FDA in Limbo as User Fee Renewal Stuck on Capitol Hill
In countdown to renewal deadline, agency already feeling the effects of still-unclear legislative fate.
New Legislation Overhauls Medicare Drug Pricing and Benefits
Pharma loses battle to block price negotiations, but implementation faces many challenges.
Senate Advances Drug Price Negotiations
Democrats approve curbs for Medicare plans, but not for commercial drug coverage.